Enliven Therapeutics Inc. (NYSE: ELVN) — Healthcare · Share Price, Chart & Market Data
About: Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $44.69 (+0.99%)
ELVNEnliven Therapeutics Inc.
Loading watchlist status…
Trade ELVN now
Enliven Therapeutics Inc. share price
ELVN price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 5:54 pm GMT+0
ELVN price performance
-2.615%
5D
15.091%
1M
187.58%
YTD
136.33%
1Y
ELVN price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 5:54 pm GMT+0
ELVN details
ELVN Market Signals